Your session is about to expire
← Back to Search
AMT-101 for Ulcerative Colitis
Study Summary
This study is evaluating whether a drug called AMT-101 may help treat ulcerative colitis.
- Ulcerative Colitis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there still opportunities for participants to join this scientific investigation?
"According to clinicaltrials.gov, this medicinal investigation is no longer recruiting patients, having been posted on August 26th 2020 and last updated November 3rd 2022. Fortunately, there are 406 other studies actively seeking volunteers at present."
Is there an age limit for individuals seeking to participate in this trial?
"The age range for participation in this medical trial is between 18 and 80. On the other hand, there are 70 trials designed specifically for minors under 18 years old and 345 clinical studies open to those who exceed 65 years of age."
Who is eligible to enroll in this trial?
"This medical trial is recruiting 105 individuals with colitis, ulcerative aged between 18 and 80. To be eligible for the study, applicants must meet these prerequisites: of both genders between ages 18 to 75 years old, female participants able to prove their non-pregnancy status prior to randomization visit and participation in all aspects of this clinical research project."
How many establishments are hosting this trial?
"This research initiative is being conducted across a variety of medical centres, including Vanderbilt University Medical Center in Nashville, Utah, University of Utah Hospitals and Clinics in Salt Lake City, Washington, and Gastro One in Germantown. Furthermore there are 20 other sites participating globally."
To what extent is AMT-101 deemed a safe treatment option?
"Our team at Power assessed AMT-101's safety to be a 2 on the scale of 1 to 3 as it is only in Phase 2, thus there is information confirming its security but no efficacy data yet."
Share this study with friends
Copy Link
Messenger